SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Teslas quarterly results are the main focus: earnings and revenue narrowly beat expectations, but traders are debating the sharp declines in operating income and free cash flow as shares move higher. Some attribute the bullish reaction to SpaceX merger speculation, though a deal remains uncertain.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly results are driving attention: traders are cheering strong revenue and ad growth and an upbeat outlook, while many attribute the reported earnings shortfall to a one-time legal charge. Debate centers on rising AI spending, cash burn and planned nonvoting share issuancebulls see investment in future AI growth, while bears worry about returns and dilution.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Researchs earnings report is driving attention: traders cite a quarterly beat, but shares sold off as investors weigh whether the outlook and guidance can justify high expectations. Some see the pullback as a buying opportunity, while others view it as a sell-the-news reaction and remain cautious about valuation and peak-demand risks.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBMs quarterly results beat revenue and earnings expectations, and the company raised its full-year free-cash-flow outlook, prompting a positive share reaction. Traders welcomed the stronger cash-flow guidance but debated weak mainframe sales, softer consulting, and narrower-than-expected margins.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is drawing attention amid continued share-price weakness and concerns about slowing core Celsius sales, Nielsen trends, and margin pressure; traders are watching upcoming earnings for evidence of a turnaround. Bulls point to Alani Nu growth and insider purchases, while talk of a Pepsi buyout remains speculation.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is drawing attention as an AI data-center power play after comments that electricity and cooling are bottlenecks to AI expansion, reinforced by fuel-cell project news and anticipation of Q3 results. Bulls see demand supporting growth, while skeptics point to the premium valuation and warn that earnings could bring more volatility or a sell-the-news reaction.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp

Discussion centers on reports that the Navy halted further purchases of BlackSeas GARC drone boats, prompting a steep selloff in AVEX. Bears view the loss as a serious blow to the acquisition and contract outlook, while bulls argue GARC is only one part of the business and point to other Navy programs and potential contract remedies.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

SLV is drawing attention amid a sharp, volatile pullback in silver, which traders often attribute to rising yields and a stronger dollar. Bears see further downside after the metals earlier surge, while long-term holders are buying dips and some traders blame paper-market shorting, citing supply concerns and industrial demand.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas investor presentation and the pending Phase 3 HLP003 readout for major depressive disorder, expected in Q4 2026. Traders are split between optimism about the programs earlier results and concern about whether efficacy will hold up in Phase 3, with financing needs and volatile price action adding to the debate.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is centered on the full Phase 3 INTerpath-001 melanoma vaccine data at ESMO, with traders focused on the magnitude and durability of benefit after the trial met key endpoints. Bulls see the cancer-vaccine pipeline as a major growth opportunity and point to squeeze momentum, while skeptics argue the run-up has outrun fundamentals and could reverse on a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SCYNEXIS Scores a Potential $214M Government Payday

BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Equity

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next 

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers

Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion.
SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%read more...

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session.
SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is atread more...

AutoZone, Zscaler And 3 Stocks To Watch Heading Into Tuesday

U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, SCYNEXIS, Box, and Zscaler after the closing bell.read more...

Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up

(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million...

  Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market

The biotech firm announced a deal to acquire a potential treatment for a kidney disease and secured $40 million through a private placement.

SCYNEXIS Q4 Earnings Assessment

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Scynexis Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Lilly will present Phase 2 results for its eloraTZP combination at the EASD meeting in Milan.</li><li>SAB BIO, Sana and Century will present type 1 diabetes research at different stages of development.</li><li>uniQure expects a four-year AMT-130 update by quarter-end and Scynexis has guided to two Phase 1 updates.</li></ul><p>Biotech investors face a crowded final week of September as Eli Lilly (LLY) and Novo Nordisk (NVO) bring their latest obesity and diabetes research to a major medical meeting in Milan, while uniQure (QURE) and Scynexis (SCYX) approach quarter-end targets for clinical updates that could put smaller stocks in the spotlight.&nbsp;</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> gained 1.8% last week, outperforming the broader market’s<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which rose 1.3%, but trailing the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, which climbed 3.3%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> advanced 2.6%, beating both <a class="mention" data-mention="$XLV" data-symbol-id="XLV" href="https://stocktwits.com/symbol/XLV" target="_blank">XLV</a> and SPY while lagging QQQ. The<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> fell 1.1%.&nbsp;</p><p><img src="https://news.stocktwits-cdn.com/healthcare_fef01ed028.png" alt="healthcare.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/ Event</td><td>Development</td></tr><tr><td>Sept.28</td><td>CAMP</td><td>Camp4 Therapeutics holds an analyst day on its CMP-002 trial for SYNGAP1-related disorder.</td></tr><tr><td>Sept.28-Oct.2</td><td>EASD</td><td>Lilly, Novo and smaller biotech companies present diabetes and obesity research in Milan.</td></tr><tr><td>Sept.29</td><td>NVO, KURA</td><td>Novo presents CagriSema analyses, while Kura affiliate Caspian Therapeutics presents preclinical KO-7246 research.</td></tr><tr><td>Sept.30</td><td>LLY, NVO, SABS</td><td>Lilly presents Phase 2 eloraTZP results; Novo has several pipeline sessions; SAB BIO discusses SAB-142.</td></tr><tr><td>By Sept.30</td><td>QURE, SCYX</td><td>Potential four-year AMT-130 update from uniQure and two Phase 1 topline updates from Scynexis.</td></tr><tr><td>Oct.1</td><td>LLY, FDA</td><td>Lilly presents Foundayo data; an FDA panel discusses influenza vaccine strain selection.</td></tr><tr><td>Oct.2</td><td>SANA, IPSC</td><td>Sana and Century present separate type 1 diabetes cell-therapy programs.</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Lilly, Novo Put Next Obesity Drugs On Display&nbsp;</strong></h2><p>The European Association for the Study of Diabetes’ annual meeting runs Monday through Friday in Milan, with obesity and diabetes presentations from Eli Lilly and Novo Nordisk. The program also includes type 1 diabetes research from SAB BIO (SABS), Sana Biotechnology (SANA) and Century Therapeutics (IPSC).<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.easd.org/annual-meeting/?utm_source=chatgpt.com">&nbsp;</a></p><p>On Wednesday, Lilly will present Phase 2 results for eloraTZP, a combination of the amylin-targeting drug Eloralintide and Tirzepatide, the ingredient in Mounjaro and Zepbound. The study involves adults with obesity or overweight and type 2 diabetes. Lilly will also discuss Phase 3 findings for Retatrutide, which targets three hormone receptors, and results from Surpass-CVOT, a study of Tirzepatide’s cardiovascular outcomes. Thursday’s session covers Phase 3 findings for its oral diabetes drug Foundayo, or Orforglipron. Lilly has already disclosed headline results from several of these studies and the presentations will add more details.</p><p>Novo has 44 abstracts at the meeting. Tuesday’s presentations include Reimagine 1 analyses of CagriSema’s effects on body composition and combined blood-sugar and weight-loss goals. On Wednesday, Novo will discuss CagriSema’s effects on appetite and responses to food cues, and present Phase 2b results for Zenagamtide, also known as Amycretin.</p><h2 class="st-heading-2"><strong>Smaller Biotechs Target Type 1 Diabetes&nbsp;</strong></h2><p>SAB BIO (SABS) will present research on SAB-142, an immunotherapy for type 1 diabetes, on Monday and Wednesday. Its Phase 1 findings address repeat dosing and early C-peptide signals. C-peptide helps show how much insulin a patient’s body still produces.</p><p>Friday features two cell-therapy programs at different stages. Sana Biotechnology (SANA) will discuss findings from a first-in-human study involving engineered donor insulin-producing cells transplanted into one patient without immunosuppressive drugs. Century Therapeutics (IPSC) will present preclinical research on manufacturing engineered stem-cell-derived insulin-producing cells for its CNTY-813 program.&nbsp;</p><p>Kura Oncology (KURA) is also linked to the diabetes program. Its separately financed affiliate, Caspian Therapeutics, will present Tuesday on KO-7246, an experimental drug being studied for its potential to increase insulin-producing beta cells.&nbsp;</p><h2 class="st-heading-2"><strong>Beyond Milan: 3 More Events To Watch This Week&nbsp;</strong></h2><p>Sellas Life Sciences (SLS) is also in focus as the AACR pancreatic-cancer conference concludes on Monday. The company released preclinical findings on its experimental drug SLS009 on Friday, ahead of three poster presentations&nbsp;that happened on Sunday. The studies examined SLS009 in pancreatic-cancer models, including combinations designed to address treatment resistance.</p><p>Camp4 Therapeutics (CAMP) has a confirmed event on Monday. Its analyst day will cover the design of a first-in-human Phase 1/2 trial of CMP-002 for Syngap1-related disorder. CAMP4 expects to start the trial in the fourth quarter.</p><p>Meanwhile, the FDA’s vaccine advisory committee is scheduled to meet on Thursday to recommend influenza virus strains for vaccines intended for the 2027 Southern Hemisphere season. Its recommendations are nonbinding.</p><h2 class="st-heading-2"><strong>Quarter-End Data Clock Ticks For QURE, SCYX&nbsp;</strong></h2><p>Outside the conference, uniQure (QURE) intends to present a four-year analysis of its AMT-130 gene-therapy studies in Huntington’s disease before the third quarter ends on Wednesday. The firm’s earlier guidance said the update would include four years of follow-up on 24 patients in its first two treatment cohorts.&nbsp;</p><p>uniQure submitted AMT-130 applications to U.S. and U.K. regulators earlier this month, supported by an earlier three-year analysis. The pending four-year update is a separate milestone. The company has requested priority review in the U.S.</p><p>Additionally, Scynexis (SCYX) has guided to two Phase 1 topline updates in the third quarter. Results for SCY-770, a potential treatment for inherited polycystic kidney disease, are expected to help select doses for a Phase 2 study. The other update concerns an intravenous version of SCY-247, an experimental antifungal.&nbsp;</p><h2 class="st-heading-2"><strong>Moderna’s Melanoma Details Remain Pending&nbsp;</strong></h2><p>Moderna (MRNA) and Merck (MRK) announced in August that their Phase 3 INTerpath-001 trial met its goals for delaying melanoma recurrence and the spread of cancer to distant parts of the body. The trial tested Moderna’s individualized cancer treatment Intismeran with Merck’s Keytruda after patients’ tumors had been surgically removed.&nbsp;</p><p>Investors are still awaiting the detailed results. The companies plan to present them at an “international medical meeting,” but have not named the conference or date.&nbsp;</p><h2 class="st-heading-2"><strong>LLY, NVO, QURE: How Do Retail Traders Feel?</strong></h2><p>Retail traders on Stocktwits turned more upbeat on LLY and QURE, even as chatter cooled. Sentiment on LLY improved to ‘neutral’ from ‘bearish’ over the past week, while message volume fell 10%. QURE sentiment rose to ‘bullish’ from ‘neutral’ a week ago, despite a 33% drop in 24-hour message volume.&nbsp;</p><p>NVO drew the most optimistic response: sentiment was ‘extremely bullish’ as message volume surged 100% over the past week.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stla-f-gm-trump-fuel-economy-rollback-auto-plants-coming-back/cZMSWm8RBfh">STLA, F, GM Climb Overnight As Trump Clears Fuel Economy Rollback — Says Auto Plants Are ‘Coming Back’&nbsp;</a></p>

Representative Image (Photo credit: Getty Images)

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch

iShares Biotechnology ETF

Century Therapeutics Inc

Lilly(Eli) & Co

Merck & Co Inc

Novo Nordisk A/S

uniQure NV

SAB Biotherapeutics Inc

Sana Biotechnology Inc

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$3.79
Prev Close	$3.80
Open	$3.89
Dividend Yield	0.00%
50-Day Moving Average	$4.76
Beta	1.16
Avg. Volume	462,688.56
PE Ratio	-2.06

52-Week High	$9.12
52-Week Low	$3.53
Market Capitalization	$37.81M
EPS (Annual)	-$1.38
Price to Book	0.56
Revenue Per Employee	$1.14M

Feed

News

Sentiment

Earnings

Fundamentals

Info

SCYX Fundamentals